These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24874279)

  • 21. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial health effects of Chios Gum Mastic and peroxisome proliferator-activated receptors: indications of common mechanisms.
    Georgiadis I; Karatzas T; Korou LM; Katsilambros N; Perrea D
    J Med Food; 2015 Jan; 18(1):1-10. PubMed ID: 25133901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G; Staels B
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk.
    Fuentes E; Palomo I
    Thromb Res; 2014 Aug; 134(2):221-6. PubMed ID: 24830902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New mechanisms of antiplatelet activity of nifedipine, an L-type calcium channel blocker.
    Chou TC
    Biomedicine (Taipei); 2014; 4(4):24. PubMed ID: 25520937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
    Sepúlveda C; Palomo I; Fuentes E
    Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease.
    Fiévet C; Staels B
    Curr Atheroscler Rep; 2009 Jul; 11(4):281-8. PubMed ID: 19500491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk.
    Millar JS
    Curr Opin Lipidol; 2013 Jun; 24(3):233-8. PubMed ID: 23594710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptors and angiogenesis.
    Biscetti F; Straface G; Pitocco D; Zaccardi F; Ghirlanda G; Flex A
    Nutr Metab Cardiovasc Dis; 2009 Dec; 19(11):751-9. PubMed ID: 19628379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
    Nicholls SJ; Uno K
    Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
    Huang Y; Zhang H; Shao Z; O'Hara KA; Kopilas MA; Yu L; Netticadan T; Anderson HD
    Cardiovasc Res; 2011 May; 90(2):267-75. PubMed ID: 21183507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging small molecule drugs.
    Colin S; Chinetti-Gbaguidi G; Kuivenhoven JA; Staels B
    Handb Exp Pharmacol; 2015; 224():617-30. PubMed ID: 25523004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.